HomeMerck

Merck

Merck’s KEYFORM-007 Study Fails to Meet Colorectal Cancer Goals

Merck’s KEYFORM-007 Study Fails to Meet Colorectal Cancer Goals

September 26, 2024

Merck’s Keytruda Gains First FDA Approval for Mesothelioma Treatment

Merck’s Keytruda Gains First FDA Approval for Mesothelioma Treatment

September 19, 2024

Merck to Acquire Ophthalmology Biotech Company EyeBio

Merck to Acquire Ophthalmology Biotech Company EyeBio

May 30, 2024

Merck’s Combination Therapy Fails Phase III Lung Cancer Study

Merck’s Combination Therapy Fails Phase III Lung Cancer Study

March 22, 2024

FDA Rejects Merck’s Chronic Cough Drug for Second Time

FDA Rejects Merck’s Chronic Cough Drug for Second Time

December 21, 2023

FDA Expands Merck’s Welireg Label for Advanced Renal Cell Carcinoma

FDA Expands Merck’s Welireg Label for Advanced Renal Cell Carcinoma

December 15, 2023

Merck Faces Setback as Keytruda-Lynparza Combo Fails Lung Cancer Study

Merck Faces Setback as Keytruda-Lynparza Combo Fails Lung Cancer Study

December 8, 2023

Merck’s Keytruda Receives FDA Approval for Expanded Use in Gastric Cancer

Merck’s Keytruda Receives FDA Approval for Expanded Use in Gastric Cancer

November 17, 2023

Merck’s Keytruda Secures Sixth FDA Approval for NSCLC

Merck’s Keytruda Secures Sixth FDA Approval for NSCLC

October 17, 2023

Merck’s Keytruda Granted EU Approval for Gastric Cancer Treatment

Merck’s Keytruda Granted EU Approval for Gastric Cancer Treatment

August 30, 2023

1 2 »